why choose us

Clinical Trials Search

Showing 16,170 of 132,963 result(s)
Comparing Nose & Mouth Breathing During Exercise

Status: COMPLETED

Condition: Healthy

Interventions: Participants will breathe only through their nose (mouth closed) during rest and submaximal exercise.

Date: 2023-01-19

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Status: Completed

Condition: Melanoma (Skin)

Interventions: Given by IV (vein)

Date: 2023-01-19

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Status: Completed

Condition: Cancer

Interventions: Solution for SC administration

Date: 2023-01-19

IO vs IV Vancomycin in Tourniquetless TKA

Status: Completed

Condition: Infection, Surgical Site

Interventions: • IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and drapi

Date: 2023-01-19

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Status: COMPLETED

Condition: Opioid Use Disorder

Interventions: Administered as a subcutaneous injection.

Date: 2023-01-19

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Status: Completed

Condition: Shingles

Interventions: Intramuscular injection

Date: 2023-01-19

taVNS or TMS or Both for Depression

Status: Completed

Condition: Depression

Interventions: All taVNS sessions will use the following parameters: 25Hz, 500us pulse width, on for 7 seconds, off for 12 seconds.The length of VNS treatment sessio

Date: 2023-01-18

COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study

Status: Completed

Condition: Chronic Migraine, Headache

Interventions: OnabotulinumtoxinA + Fremanezumab 225mg;1.5mL

Date: 2023-01-18

A Study of EBC-129 in Advanced Solid Tumours

Status: Completed

Condition: Advanced Solid Tumours

Interventions: EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-90-minute intravenous (IV) fusion.

Date: 2023-01-18

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

Status: Completed

Condition: Stress Urinary Incontinence

Interventions: All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.

Date: 2023-01-18